Operator of a healthcare company intended for the treatment of respiratory conditions. The company leverages a deuterated small-molecule approach to enhance tolerability and facilitate oral administration, enabling healthcare providers to address the limitations of existing treatments through stabilized lung function, reduced adverse effects, and optimized dosing for chronic disease management.
All entries for: Investment
June 24, 2026
Saturnus Bio
Investment
Developer of therapeutic pharmaceuticals and biological therapies intended to prevent and treat cardiovascular and muscle diseases. The company includes biological preparations and pharmaceutical solutions, designed to target the underlying causes of cardiovascular and muscle disorders, enabling healthcare providers to offer targeted treatments with improved patient outcomes and support for long-term disease management.
Disease Area: Rare Diseases
June 17, 2026
Spot Biosystems
Investment
Developer of a cell sample preparation platform designed for genomic analysis, including deoxyribonucleic acid sequencing. The company’s platform uses microfluidic technology to transform the landscape of sample processing to separate and isolate cellular components, enabling healthcare and biotech companies to perform biological sample preparation.
Disease Area: Rare Diseases
June 12, 2026
X1 Biotech
Investment
Developer of small-molecule therapeutics designed for vascular repair across multiple disease indications. The company modulates a shared upstream regulatory pathway implicated in vascular and fibrotic disease, demonstrating potential in preclinical models to slow pathological progression and partially restore structural features of damaged vasculature including smooth muscle cell coverage, with biological activity observed across inherited small-vessel disease, pulmonary fibrosis, aberrant angiogenesis eye diseases, and neurodegenerative conditions, enabling rare disease and broader therapeutic markets to benefit from a capital-efficient, single-compound approach to addressing progressive vascular breakdown.
Disease Area: Rare Diseases
June 10, 2026
SonoThera
Investment
Developer of a nonviral gene therapy platform designed to provide ultrasound-mediated genetic medicines. The company’s platform utilizes microbubble-mediated sonoporation and proprietary acoustic technology to deliver diverse nucleic acid payloads to targeted organs, enabling patients with genetic diseases to access safe and cost-effective treatments without the size restrictions or immunogenicity associated with viral vectors.
Disease Area: Rare Diseases
June 3, 2026
Optimeos Life Sciences
Investment
Optimeos Life Sciences raised $1 million to advance its non-viral nanoparticle gene therapy for the treatment of Citrullinemia Type 1, a rare urea cycle disorder.
Disease Area: Rare Diseases
June 3, 2026
Goldenrod Therapeutics
Investment
Goldenrod Therapeutics raised $6.5 million to advance therapies for the treatment of Friedreich’s ataxia, a rare neurodegenerative disorder.
Disease Area: Rare Diseases
June 1, 2026
Navion
Investment
Navion received an undisclosed amount of funding to advance therapies targeting sodium and other ion channel mutations for the treatment of rare genetic epilepsies.
Disease Area: Rare Diseases
May 26, 2026
Neela Therapeutics
Investment
Neela Therapeutics raised $13.82 million to advance its pipeline of pediatric medicines for the treatment of rare neurodevelopmental and neurodegenerative disorders, including CLN3 Batten disease and Rett syndrome.
Disease Area: Rare Diseases
May 4, 2026
PharmassetX
Investment
PharmassetX raised $0.15 million to advance galenexib, an FDA-designated orphan drug for the treatment of pouchitis, a rare chronic inflammatory disease.
Disease Area: Rare Diseases